Genovate Biotechnology Co Ltd (4130) — Cash Flow-to-Debt Ratio
Genovate Biotechnology Co Ltd (4130) has a Cash Flow-to-Debt Ratio of 0.13x as of December 2025, meaning its operating cash flow of NT$16.93 Million could theoretically repay 0% of its total liabilities (NT$126.05 Million) in one year. See Genovate Biotechnology Co Ltd (4130) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Genovate Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Genovate Biotechnology Co Ltd across 11 annual periods. For the full cash flow conversion analysis, see 4130 cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Genovate Biotechnology Co Ltd (2015–2025)
Year-by-year debt coverage analysis for Genovate Biotechnology Co Ltd. Check Genovate Biotechnology Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.35x | NT$43.79 Million | NT$126.05 Million | ▼ -11.1% |
| 2024 | 0.39x | NT$55.11 Million | NT$141.08 Million | ▼ -39.3% |
| 2023 | 0.64x | NT$84.78 Million | NT$131.69 Million | ▲ +6449.1% |
| 2022 | 0.01x | NT$1.51 Million | NT$153.60 Million | ▲ +107.8% |
| 2021 | -0.13x | NT$-17.26 Million | NT$136.65 Million | ▼ -121.0% |
| 2020 | 0.60x | NT$87.08 Million | NT$144.87 Million | ▲ +122.8% |
| 2019 | 0.27x | NT$44.43 Million | NT$164.68 Million | ▼ -26.1% |
| 2018 | 0.36x | NT$62.88 Million | NT$172.32 Million | ▲ +415.8% |
| 2017 | 0.07x | NT$31.27 Million | NT$442.06 Million | ▼ -60.2% |
| 2016 | 0.18x | NT$70.58 Million | NT$397.04 Million | ▲ +114.7% |
| 2015 | 0.08x | NT$32.53 Million | NT$392.95 Million | — |